申请人:Dermavant Sciences GmbH
公开号:US10206925B2
公开(公告)日:2019-02-19
Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.
本发明的实施方案涉及由式(I)代表的化合物、其盐、代谢物、原药或水合物连同溶剂和碱的局部制剂。该化合物是一种 PDE4 抑制剂,外用制剂可用于治疗皮肤病,例如但不限于特应性皮炎、脂溢性皮炎、脱发、接触性皮炎、银屑病、荨麻疹、湿疹、烧伤、晒伤、胰腺炎、肝炎、扁平苔藓、硬皮病、硬皮病、皮肌炎、与前述任何病症相关的瘙痒或其组合。